Axon Enterprise, Inc. (NASDAQ:AXON) Short Interest Up 14.7% in January

Axon Enterprise, Inc. (NASDAQ:AXONGet Free Report) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,570,000 shares, an increase of 14.7% from the December 31st total of 2,240,000 shares. Based on an average daily trading volume, of 883,200 shares, the short-interest ratio is currently 2.9 days.

Axon Enterprise Price Performance

AXON stock opened at $652.18 on Monday. Axon Enterprise has a 1 year low of $247.04 and a 1 year high of $698.67. The firm has a 50-day moving average of $619.63 and a 200 day moving average of $483.68. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The company has a market cap of $49.73 billion, a P/E ratio of 168.52, a PEG ratio of 6.41 and a beta of 1.04.

Wall Street Analysts Forecast Growth

AXON has been the subject of several research analyst reports. Robert W. Baird raised their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. TD Cowen initiated coverage on shares of Axon Enterprise in a report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price target for the company. Northland Securities increased their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $500.00 to $700.00 in a report on Tuesday, December 3rd. Finally, Needham & Company LLC increased their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $524.85.

Check Out Our Latest Stock Report on Axon Enterprise

Insider Activity at Axon Enterprise

In related news, Director Julie A. Cullivan sold 1,261 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $682.06, for a total value of $860,077.66. Following the transaction, the director now directly owns 2,392 shares in the company, valued at $1,631,487.52. This trade represents a 34.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jeffrey C. Kunins sold 21,834 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $593.88, for a total transaction of $12,966,775.92. Following the completion of the transaction, the insider now directly owns 154,394 shares in the company, valued at approximately $91,691,508.72. The trade was a 12.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,545 shares of company stock worth $30,721,337 over the last quarter. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AXON. Creative Planning raised its stake in Axon Enterprise by 9.6% during the second quarter. Creative Planning now owns 16,463 shares of the biotechnology company’s stock valued at $4,844,000 after buying an additional 1,441 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in Axon Enterprise by 30.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 802 shares of the biotechnology company’s stock valued at $236,000 after buying an additional 188 shares during the last quarter. EP Wealth Advisors LLC raised its stake in shares of Axon Enterprise by 18.3% in the second quarter. EP Wealth Advisors LLC now owns 1,577 shares of the biotechnology company’s stock worth $464,000 after buying an additional 244 shares during the period. Truist Financial Corp lifted its holdings in Axon Enterprise by 53.4% during the second quarter. Truist Financial Corp now owns 6,467 shares of the biotechnology company’s stock valued at $1,903,000 after purchasing an additional 2,251 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in shares of Axon Enterprise by 11.8% in the second quarter. Cetera Investment Advisers now owns 23,546 shares of the biotechnology company’s stock worth $6,928,000 after acquiring an additional 2,479 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Read More

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.